A Playbook for Monitoring Ambient AI After Go-Live
Deploying ambient AI is the start of the work that protects patients. The monitoring playbook I stand up on day one.
Photo by Filip Szyller on Pexels
Deploying ambient AI is not the finish line, it is the start of the part that actually protects patients: monitoring. A recent NEJM AI playbook makes the case that you should run a live ambient-AI deployment like an ongoing pragmatic trial, watching it in production, not just certifying it once. Here is the monitoring playbook I would put in place on day one.
The demo ends, the ambient AI goes live, everyone celebrates, and then most teams stop watching. That is the mistake. In my experience the risky period for ambient AI is not the pilot, it is the quiet months after go-live, when the model drifts, the edge cases pile up, and nobody is looking. A recent NEJM AI playbook makes this case well: treat a live ambient-AI deployment like an ongoing pragmatic trial, and monitor it in production rather than certifying it once and walking away. The full paper is indexed on PubMed. Here is the monitoring playbook I would stand up on day one.
The core idea is simple. Deployment is not the end of evaluation, it is the beginning of it. An ambient AI that was safe in a trial can drift, meet a new population, or quietly degrade, and the only way you find out before a patient does is by watching. So I build the monitoring in before I turn the tool on, and I treat the metrics as seriously as the launch.
Watch four things, always
You cannot watch everything, so I watch the four signals that catch almost every real problem. Whether the output quality is drifting from where it launched. How often clinicians edit or override it, because a quiet rise in heavy edits is the tool failing in slow motion. Whether people are actually using it or drifting back to the old way. And any near-miss or harm, however small. Each has a red flag I do not let slide.
The monitoring routine
Here is the routine, in order. None of it is exotic, and all of it has to exist before go-live, not after the first scare.
The cadence
Monitoring effort should be front-loaded, because the first weeks after go-live are when the surprises come. I watch daily at first, then settle into a rhythm, and I re-run the whole evaluation every quarter as if I were deciding to deploy the tool for the first time. I keep this as a one-page checklist the team can pin above a desk, and I am happy to share it as a downloadable.
Ambient AI is one of the most useful tools I have seen reach clinicians, and it is also the kind that fails quietly. The difference between a deployment that stays safe and one that drifts into trouble is not the model, it is whether anyone is watching after launch. Build the monitoring first. Treat go-live as the start of the trial, not the end of the project. That is how the tool keeps earning its place.
- Deploying ambient AI is the start of evaluation, not the end.
- Run a live deployment like an ongoing pragmatic trial, watching it in production.
- Watch four things: output-quality drift, edit and override rate, adoption and abandonment, and near-misses.
- Capture a baseline at go-live so drift has something to measure against.
- Set thresholds and page owners before a metric goes bad, not after.
- Monitoring with no action is theater; always close the loop.
Frequently asked
Why monitor ambient AI after deployment?
Because models drift, meet new populations, and degrade quietly. A tool safe in a trial can become unsafe in production, and monitoring is how you catch it before a patient does.
What does it mean to treat deployment like a trial?
Keep evaluating in production: baseline at launch, log outputs, sample and review on a cadence, set thresholds, and act on what you find, as a recent NEJM AI playbook argues.
What should you monitor?
Output-quality drift, clinician edit and override rates, adoption and abandonment, and any near-misses or harm.
How often should you review?
Daily sampled review in week one, monthly drift and adoption checks, and a full quarterly re-evaluation.
What is the most common monitoring failure?
Collecting metrics but never acting on them. Monitoring only helps if findings feed retraining, retuning, or rollback.
Sources
Naveen Kumar
Healthcare engineering and product executive in Pittsburgh. 15+ years building AI-first patient access, a decade at Treatspace.